As we look ahead to 2021, we once again encourage healthcare startups to apply for the annual MedCity INVEST Pitch Perfect startup competition at the spring conference scheduled for April 19-23. You can view the criteria and submit your application here.
The deadline to apply is 5pm ET, Friday, January 15.
Finalists will compete across five tracks: biopharma, medical devices, diagnostics, health IT and health services. If these categories reflect your business, please apply.
To be eligible to participate, you need to fulfill one of the following criteria:
- Raised at least $1 million;
- Raised a Series A round;
- Have at least one qualified institutional investor or strategic investor that you can identify
Companies should also be looking for additional funding in the next 12 months. When completing the 2-page executive summary, please describe clearly the following:
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
- Unmet need in the marketplace your company seeks to address;
- Your value proposition;
- How your product works in terms of the science behind it;
- Go-to-market strategy;
- If you have results of a pilot or other examples of clinical validation, please include it.
This will help investors screen your application based on the following criteria:
- Business idea
- Market opportunity
- Revenue model
- Founder’s experience
Each category will lead to the selection of five to six startups who will be judged by a group of leading healthcare investors, both traditional and corporate VCs.
The deadline to apply is 5 pm ET, Friday, January 15. Submit your application here.
Illustration: drante, Getty Images
